Information Box Group
Vinai Bhagirath
MD, MSc, FRCPC
Associate Professor
Thrombosis AFC Program Director
Vinai Bhagirath
MD, MSc, FRCPC
Associate Professor
Thrombosis AFC Program Director
Graeme Fraser
Associate Professor
Fellowship Director, Adult Hematology Residency Program Director
Graeme Fraser
Associate Professor
Fellowship Director, Adult Hematology Residency Program Director
Alfonso Iorio
MD, PhD, FRCPC
Professor
Chair, HEI
The Health Information Research Unit (HiRU), founded by Brian Haynes, is a knowledge refinery, whose main activity is maintaining the McMaster Premium LiteratUre Service (McMaster PLUS), a second-order peer review database of methodologically sound, clinically relevant and newsworthy peer reviewed publications. McPLUS is used for many purposes, including:
- identifying candidate papers for abstraction (American College of Physicians Journal Club, a monthly feature in the of Annals of Internal Medicine);
- providing discipline specific news feeds via the DynaMed sponsored Evidence Alerts service, or the ACP sponsored JournalWise evidence feed;
- identifying candidate papers for triggering BMJ Wiki recs;
- feeding evidence into a suite of discipline specific products like Clot+, Pain+, Prevention+, the Optimal Aging Portal and, more recently, COVID-19+ EvidenceAlerts.
HiRU has created the Clinical Query filters available on the PubMed search engine and, more recently, developed a machine learning based, highly specific algorithm to retrieve sound and clinically relevant literature.
HiRU is open to potential collaborations with any academic, not-for-profit or commercial organization whose aim is to disseminate high quality evidence. For further details on HiRU’s knowledge translation research program, click here.
The clinical research program is centered on the application of information technology to optimize the clinical management of rare bleeding disorders. The McMaster Hemophilia Research Program, based and partly supported by the Michael G. DeGroote School of Medicine, runs a worldwide epidemiology and pharmacoepidemiology research program based on the following infrastructure: a) the Canadian Bleeding Disorder Registry (CBDR), supporting clinical activities of all bleeding disorder centers in Canada and feeding a central anonymized data repository; b) the Web-available Population Pharmacokinetic Service (WAPPS) and research network, the gold standard for personalized treatment for hemophilia, covering over 550 centers worldwide, producing PopPK estimates at the point of care for all available factor concentrates; c) the Patient Reported Outcome, Burden and Experiences (PROBE), a multilingual assessment tool and research network aiming to generate robust comparative effectiveness data. For further details, click here.
Teaching
Course Coordinator and Lecturer, Health Research Methodology Course #777 (Diagnosis and Prognosis)
Lecturer, Health Research Methodology Course #721 (Introduction to Health Research Methodology) Teaching Unit: Prognostic studies
Other scholarly activities
Dr. Iorio is an Associate Editor of the Cystic Fibrosis and Genetic Disorders Review Group of Cochrane, and a member of Cochrane’s Prognosis Method Group.
He is past Chair of the Data and Demographics Committee of the World Federation of Haemophilia (WFH), Co-Chair of the World Bleeding Disorder Registry (WFH), a member of the GRADE Working Group, and a member of the COVID-END initiative.
Full publication list: click here
Research Interests: knowledge translation research; medical informatics
Madeleine Verhovsek
MD, FRCPC
Professor
Chief of Medicine, St. Joseph's Healthcare
Madeleine Verhovsek
MD, FRCPC
Professor
Chief of Medicine, St. Joseph's Healthcare
Jeffrey Weitz
MD, FRCPC, FACP, FCCP
Professor, Division of Hematology & Thromboembolism
Heart and Stroke Foundation / J. Fraser Mustard Chair in Cardiovascular Research; Executive Director, Thrombosis & Atherosclerosis Research Institute; Associate Chair, Research
Dr. Weitz is Professor of Medicine and Biochemistry and Biomedical Sciences at McMaster University and Executive Director of the Thrombosis and Atherosclerosis Research Institute. Board Certified in Internal Medicine, Hematology and Medical Oncology, Dr. Weitz focuses his clinical practice on patients with thrombotic disorders. His research spans the spectrum from basic studies in the biochemistry of blood coagulation and fibrinolysis to animal models of thrombosis and on to clinical trials of antithrombotic therapy. The breadth of his work is highlighted by his over 500 publications in journals as diverse as the Journal of Clinical Investigation, Journal of Biological Chemistry, Biochemistry, Circulation, Blood, Annals of Internal Medicine, New England Journal of Medicine and Lancet, and 60 book chapters. The recipient of numerous awards, Dr. Weitz is a Fellow of the American Heart Association, the Royal Society of Canada and the Canadian Academy of Health Sciences.
By focusing on the basic mechanisms by which anticoagulants (blood thinners) and thrombolytic agents (clot digesting drugs) work, Dr. Weitz has opened new avenues of investigation. His demonstration that thrombin bound to fibrin is resistant to inactivation by available anticoagulants stimulated the development of new drugs, some of which are already being used in clinical practice. Through other research, Dr. Weitz has provided an explanation for the puzzling clinical observation that the clot digesting drug, tissue-type plasminogen activator or t-PA, produces more bleeding than was originally anticipated. This work has paved the way for new drugs that may be safer than t-PA.
Dr. Weitz is involved in clinical trials examining optimal methods for prevention, diagnosis and treatment of clotting disorders. He also is an active participant in the education of medical students, residents, and postdoctoral fellows. In addition, he coordinates a graduate course in medical sciences and his laboratory is a fertile training ground for graduate students and postdoctoral fellows in medical sciences and bioengineering.
Jeffrey Weitz
MD, FRCPC, FACP, FCCP
Professor, Division of Hematology & Thromboembolism
Heart and Stroke Foundation / J. Fraser Mustard Chair in Cardiovascular Research; Executive Director, Thrombosis & Atherosclerosis Research Institute; Associate Chair, Research
Vinai Bhagirath
MD, MSc, FRCPC
Associate Professor
Thrombosis AFC Program Director
Vinai Bhagirath
MD, MSc, FRCPC
Associate Professor
Thrombosis AFC Program Director
Graeme Fraser
Associate Professor
Fellowship Director, Adult Hematology Residency Program Director
Graeme Fraser
Associate Professor
Fellowship Director, Adult Hematology Residency Program Director
Alfonso Iorio
MD, PhD, FRCPC
Professor
Chair, HEI
The Health Information Research Unit (HiRU), founded by Brian Haynes, is a knowledge refinery, whose main activity is maintaining the McMaster Premium LiteratUre Service (McMaster PLUS), a second-order peer review database of methodologically sound, clinically relevant and newsworthy peer reviewed publications. McPLUS is used for many purposes, including:
- identifying candidate papers for abstraction (American College of Physicians Journal Club, a monthly feature in the of Annals of Internal Medicine);
- providing discipline specific news feeds via the DynaMed sponsored Evidence Alerts service, or the ACP sponsored JournalWise evidence feed;
- identifying candidate papers for triggering BMJ Wiki recs;
- feeding evidence into a suite of discipline specific products like Clot+, Pain+, Prevention+, the Optimal Aging Portal and, more recently, COVID-19+ EvidenceAlerts.
HiRU has created the Clinical Query filters available on the PubMed search engine and, more recently, developed a machine learning based, highly specific algorithm to retrieve sound and clinically relevant literature.
HiRU is open to potential collaborations with any academic, not-for-profit or commercial organization whose aim is to disseminate high quality evidence. For further details on HiRU’s knowledge translation research program, click here.
The clinical research program is centered on the application of information technology to optimize the clinical management of rare bleeding disorders. The McMaster Hemophilia Research Program, based and partly supported by the Michael G. DeGroote School of Medicine, runs a worldwide epidemiology and pharmacoepidemiology research program based on the following infrastructure: a) the Canadian Bleeding Disorder Registry (CBDR), supporting clinical activities of all bleeding disorder centers in Canada and feeding a central anonymized data repository; b) the Web-available Population Pharmacokinetic Service (WAPPS) and research network, the gold standard for personalized treatment for hemophilia, covering over 550 centers worldwide, producing PopPK estimates at the point of care for all available factor concentrates; c) the Patient Reported Outcome, Burden and Experiences (PROBE), a multilingual assessment tool and research network aiming to generate robust comparative effectiveness data. For further details, click here.
Teaching
Course Coordinator and Lecturer, Health Research Methodology Course #777 (Diagnosis and Prognosis)
Lecturer, Health Research Methodology Course #721 (Introduction to Health Research Methodology) Teaching Unit: Prognostic studies
Other scholarly activities
Dr. Iorio is an Associate Editor of the Cystic Fibrosis and Genetic Disorders Review Group of Cochrane, and a member of Cochrane’s Prognosis Method Group.
He is past Chair of the Data and Demographics Committee of the World Federation of Haemophilia (WFH), Co-Chair of the World Bleeding Disorder Registry (WFH), a member of the GRADE Working Group, and a member of the COVID-END initiative.
Full publication list: click here
Research Interests: knowledge translation research; medical informatics
Alfonso Iorio
MD, PhD, FRCPC
Professor
Chair, HEI
The Health Information Research Unit (HiRU), founded by Brian Haynes, is a knowledge refinery, whose main activity is maintaining the McMaster Premium LiteratUre Service (McMaster PLUS), a second-order peer review database of methodologically sound, clinically relevant and newsworthy peer reviewed publications. McPLUS is used for many purposes, including:
- identifying candidate papers for abstraction (American College of Physicians Journal Club, a monthly feature in the of Annals of Internal Medicine);
- providing discipline specific news feeds via the DynaMed sponsored Evidence Alerts service, or the ACP sponsored JournalWise evidence feed;
- identifying candidate papers for triggering BMJ Wiki recs;
- feeding evidence into a suite of discipline specific products like Clot+, Pain+, Prevention+, the Optimal Aging Portal and, more recently, COVID-19+ EvidenceAlerts.
HiRU has created the Clinical Query filters available on the PubMed search engine and, more recently, developed a machine learning based, highly specific algorithm to retrieve sound and clinically relevant literature.
HiRU is open to potential collaborations with any academic, not-for-profit or commercial organization whose aim is to disseminate high quality evidence. For further details on HiRU’s knowledge translation research program, click here.
The clinical research program is centered on the application of information technology to optimize the clinical management of rare bleeding disorders. The McMaster Hemophilia Research Program, based and partly supported by the Michael G. DeGroote School of Medicine, runs a worldwide epidemiology and pharmacoepidemiology research program based on the following infrastructure: a) the Canadian Bleeding Disorder Registry (CBDR), supporting clinical activities of all bleeding disorder centers in Canada and feeding a central anonymized data repository; b) the Web-available Population Pharmacokinetic Service (WAPPS) and research network, the gold standard for personalized treatment for hemophilia, covering over 550 centers worldwide, producing PopPK estimates at the point of care for all available factor concentrates; c) the Patient Reported Outcome, Burden and Experiences (PROBE), a multilingual assessment tool and research network aiming to generate robust comparative effectiveness data. For further details, click here.
Teaching
Course Coordinator and Lecturer, Health Research Methodology Course #777 (Diagnosis and Prognosis)
Lecturer, Health Research Methodology Course #721 (Introduction to Health Research Methodology) Teaching Unit: Prognostic studies
Other scholarly activities
Dr. Iorio is an Associate Editor of the Cystic Fibrosis and Genetic Disorders Review Group of Cochrane, and a member of Cochrane’s Prognosis Method Group.
He is past Chair of the Data and Demographics Committee of the World Federation of Haemophilia (WFH), Co-Chair of the World Bleeding Disorder Registry (WFH), a member of the GRADE Working Group, and a member of the COVID-END initiative.
Full publication list: click here
Research Interests: knowledge translation research; medical informatics
Madeleine Verhovsek
MD, FRCPC
Professor
Chief of Medicine, St. Joseph's Healthcare
Madeleine Verhovsek
MD, FRCPC
Professor
Chief of Medicine, St. Joseph's Healthcare
Jeffrey Weitz
MD, FRCPC, FACP, FCCP
Professor, Division of Hematology & Thromboembolism
Heart and Stroke Foundation / J. Fraser Mustard Chair in Cardiovascular Research; Executive Director, Thrombosis & Atherosclerosis Research Institute; Associate Chair, Research
Dr. Weitz is Professor of Medicine and Biochemistry and Biomedical Sciences at McMaster University and Executive Director of the Thrombosis and Atherosclerosis Research Institute. Board Certified in Internal Medicine, Hematology and Medical Oncology, Dr. Weitz focuses his clinical practice on patients with thrombotic disorders. His research spans the spectrum from basic studies in the biochemistry of blood coagulation and fibrinolysis to animal models of thrombosis and on to clinical trials of antithrombotic therapy. The breadth of his work is highlighted by his over 500 publications in journals as diverse as the Journal of Clinical Investigation, Journal of Biological Chemistry, Biochemistry, Circulation, Blood, Annals of Internal Medicine, New England Journal of Medicine and Lancet, and 60 book chapters. The recipient of numerous awards, Dr. Weitz is a Fellow of the American Heart Association, the Royal Society of Canada and the Canadian Academy of Health Sciences.
By focusing on the basic mechanisms by which anticoagulants (blood thinners) and thrombolytic agents (clot digesting drugs) work, Dr. Weitz has opened new avenues of investigation. His demonstration that thrombin bound to fibrin is resistant to inactivation by available anticoagulants stimulated the development of new drugs, some of which are already being used in clinical practice. Through other research, Dr. Weitz has provided an explanation for the puzzling clinical observation that the clot digesting drug, tissue-type plasminogen activator or t-PA, produces more bleeding than was originally anticipated. This work has paved the way for new drugs that may be safer than t-PA.
Dr. Weitz is involved in clinical trials examining optimal methods for prevention, diagnosis and treatment of clotting disorders. He also is an active participant in the education of medical students, residents, and postdoctoral fellows. In addition, he coordinates a graduate course in medical sciences and his laboratory is a fertile training ground for graduate students and postdoctoral fellows in medical sciences and bioengineering.
Jeffrey Weitz
MD, FRCPC, FACP, FCCP
Professor, Division of Hematology & Thromboembolism
Heart and Stroke Foundation / J. Fraser Mustard Chair in Cardiovascular Research; Executive Director, Thrombosis & Atherosclerosis Research Institute; Associate Chair, Research
Dr. Weitz is Professor of Medicine and Biochemistry and Biomedical Sciences at McMaster University and Executive Director of the Thrombosis and Atherosclerosis Research Institute. Board Certified in Internal Medicine, Hematology and Medical Oncology, Dr. Weitz focuses his clinical practice on patients with thrombotic disorders. His research spans the spectrum from basic studies in the biochemistry of blood coagulation and fibrinolysis to animal models of thrombosis and on to clinical trials of antithrombotic therapy. The breadth of his work is highlighted by his over 500 publications in journals as diverse as the Journal of Clinical Investigation, Journal of Biological Chemistry, Biochemistry, Circulation, Blood, Annals of Internal Medicine, New England Journal of Medicine and Lancet, and 60 book chapters. The recipient of numerous awards, Dr. Weitz is a Fellow of the American Heart Association, the Royal Society of Canada and the Canadian Academy of Health Sciences.
By focusing on the basic mechanisms by which anticoagulants (blood thinners) and thrombolytic agents (clot digesting drugs) work, Dr. Weitz has opened new avenues of investigation. His demonstration that thrombin bound to fibrin is resistant to inactivation by available anticoagulants stimulated the development of new drugs, some of which are already being used in clinical practice. Through other research, Dr. Weitz has provided an explanation for the puzzling clinical observation that the clot digesting drug, tissue-type plasminogen activator or t-PA, produces more bleeding than was originally anticipated. This work has paved the way for new drugs that may be safer than t-PA.
Dr. Weitz is involved in clinical trials examining optimal methods for prevention, diagnosis and treatment of clotting disorders. He also is an active participant in the education of medical students, residents, and postdoctoral fellows. In addition, he coordinates a graduate course in medical sciences and his laboratory is a fertile training ground for graduate students and postdoctoral fellows in medical sciences and bioengineering.